You're contacting media contact of this press release

Title: GLP-1 Patients Regain Most of Their Lost Weight Within 2 Years . A Tampa Telehealth Provider Is Partnering With a Digital Health Platform to Change That.

United States, 12th Jun 2026 - GLP-1 medications such as compounded semaglutide and tirzepatide have changed what is possible in weight loss care. For the first time in decades, patients are seeing reductions of 15 to 20 percent of body weight, with improvements in blood sugar, blood pressure, and cardiovascular markers that were once reserved for surgery. There is, however, a quieter problem unfolding behind those headlines. Roughly half of patients stop GLP-1 therapy within twelve months, and most regain a significant portion of the weight they lost. A January 2026 systematic review in The BMJ, drawing on 37 studies and more than 9,000 adults, found that weight returns at a rate of about 0.4 kilograms per month after stopping medication. At that pace, the average patient is back at baseline within 1.5 to 2 years. "GLP-1 therapy is one of the most powerful tools we have, but it was never designed to be the whole solution," said a spokesperson for Precision Telemed, a Tampa-based telehealth provider specializing in compounded GLP-1, sermorelin, testosterone, and anti-aging programs. "What patients need around the medication is the part that most clinics have not solved. That is exactly what this partnership was built for." The Missing Piece in Metabolic Care In May 2025, four of the largest organizations in the field, the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, jointly released a clinical advisory on GLP-1 use. Their central finding was direct: most patients prescribed GLP-1s do not receive adequate nutritional counseling or behavioral support, and outcomes suffer as a result. The advisory noted that pairing GLP-1 therapy with structured nutrition guid...

This press release is issued by King Newswire